Furthermore, literature showed that GLP-1 had been approved by FDA to treat obesity, served as an anti-obesity agent mainly through reducing appetite or enhancing satiety in central nervous system (Srivastava and Apovian, 2018). This evidence concerns the gene GLP1R and Obesity.